adagrasib
mirati
['nsclc', 'lcsm,(-blcsm)', 'krystal1', 'sclc', 'adagrasib']
adagrasib shows impressive data in metastatic #nsclc pts w/krasg12c mutation. produced responses in 43% of previously treated patients with nsclc containing a krasg12c mutation, with median os of 12.6 months. #krystal1 at #asco22 #lcsm
Medscape Oncology provides breaking medical news, references for drugs, diseases, and procedures, and free CME.